JP2007518760A5 - - Google Patents

Download PDF

Info

Publication number
JP2007518760A5
JP2007518760A5 JP2006549999A JP2006549999A JP2007518760A5 JP 2007518760 A5 JP2007518760 A5 JP 2007518760A5 JP 2006549999 A JP2006549999 A JP 2006549999A JP 2006549999 A JP2006549999 A JP 2006549999A JP 2007518760 A5 JP2007518760 A5 JP 2007518760A5
Authority
JP
Japan
Prior art keywords
dry weight
weight basis
pharmaceutically acceptable
tablet
dpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006549999A
Other languages
English (en)
Japanese (ja)
Other versions
JP5122144B2 (ja
JP2007518760A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/000400 external-priority patent/WO2005067976A2/en
Publication of JP2007518760A publication Critical patent/JP2007518760A/ja
Publication of JP2007518760A5 publication Critical patent/JP2007518760A5/ja
Application granted granted Critical
Publication of JP5122144B2 publication Critical patent/JP5122144B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006549999A 2004-01-20 2005-01-17 直接圧縮製剤および方法 Expired - Lifetime JP5122144B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53770604P 2004-01-20 2004-01-20
US60/537,706 2004-01-20
US60427404P 2004-08-25 2004-08-25
US60/604,274 2004-08-25
PCT/EP2005/000400 WO2005067976A2 (en) 2004-01-20 2005-01-17 Direct compression formulation and process

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012107450A Division JP5739835B2 (ja) 2004-01-20 2012-05-09 直接圧縮製剤および方法

Publications (3)

Publication Number Publication Date
JP2007518760A JP2007518760A (ja) 2007-07-12
JP2007518760A5 true JP2007518760A5 (cg-RX-API-DMAC7.html) 2008-03-06
JP5122144B2 JP5122144B2 (ja) 2013-01-16

Family

ID=34798877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006549999A Expired - Lifetime JP5122144B2 (ja) 2004-01-20 2005-01-17 直接圧縮製剤および方法
JP2012107450A Expired - Lifetime JP5739835B2 (ja) 2004-01-20 2012-05-09 直接圧縮製剤および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012107450A Expired - Lifetime JP5739835B2 (ja) 2004-01-20 2012-05-09 直接圧縮製剤および方法

Country Status (31)

Country Link
US (4) US20080038341A1 (cg-RX-API-DMAC7.html)
EP (5) EP3738585B1 (cg-RX-API-DMAC7.html)
JP (2) JP5122144B2 (cg-RX-API-DMAC7.html)
KR (1) KR101259645B1 (cg-RX-API-DMAC7.html)
AR (1) AR049000A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005205055B2 (cg-RX-API-DMAC7.html)
BR (3) BR122018014389B1 (cg-RX-API-DMAC7.html)
CA (1) CA2552569C (cg-RX-API-DMAC7.html)
CY (3) CY1110522T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005015421D1 (cg-RX-API-DMAC7.html)
DK (3) DK1715893T3 (cg-RX-API-DMAC7.html)
EC (3) ECSP066707A (cg-RX-API-DMAC7.html)
ES (4) ES2684325T5 (cg-RX-API-DMAC7.html)
HR (2) HRP20211766T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056586T2 (cg-RX-API-DMAC7.html)
IL (1) IL176831A0 (cg-RX-API-DMAC7.html)
LT (2) LT3366283T (cg-RX-API-DMAC7.html)
MA (1) MA28305A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06008265A (cg-RX-API-DMAC7.html)
MY (1) MY138450A (cg-RX-API-DMAC7.html)
NO (2) NO345116B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ578743A (cg-RX-API-DMAC7.html)
PE (1) PE20050686A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501331A1 (cg-RX-API-DMAC7.html)
PL (4) PL3738585T3 (cg-RX-API-DMAC7.html)
PT (4) PT1715893E (cg-RX-API-DMAC7.html)
RS (2) RS57561B1 (cg-RX-API-DMAC7.html)
RU (1) RU2766487C2 (cg-RX-API-DMAC7.html)
SI (3) SI1715893T1 (cg-RX-API-DMAC7.html)
TW (1) TWI374760B (cg-RX-API-DMAC7.html)
WO (1) WO2005067976A2 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5122144B2 (ja) 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
ATE537141T1 (de) 2004-02-05 2011-12-15 Kyorin Seiyaku Kk Bicycloesterderivat
BRPI0512263A (pt) * 2004-06-17 2008-02-26 Merz Pharma Gmbh & Co Kgaa formulações de liberação imediata de formas de dosagem oral de memantina
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
WO2007017423A2 (en) * 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
US20080227825A1 (en) * 2005-09-29 2008-09-18 Yatindra Joshi Formulation
EP1976522B2 (en) 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition containing montelukast
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
US7915427B2 (en) 2006-03-08 2011-03-29 Kyorin Pharmaceuticals Co., Ltd. Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
TW201350143A (zh) 2007-02-01 2013-12-16 Takeda Pharmaceutical 固體型製劑
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
JP5432720B2 (ja) 2007-03-13 2014-03-05 武田薬品工業株式会社 ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
JPWO2008114857A1 (ja) 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5476305B2 (ja) 2008-08-07 2014-04-23 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
US20110152342A1 (en) * 2008-08-14 2011-06-23 Hiroshi Uchida Stabilized pharmaceutical composition
KR101657960B1 (ko) 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
JPWO2010110436A1 (ja) 2009-03-27 2012-10-04 杏林製薬株式会社 塩基性添加剤を含有するマトリックス型徐放性製剤
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102711761B (zh) * 2009-12-18 2015-06-03 田边三菱制药株式会社 溶出稳定化制剂
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6122879B2 (ja) 2012-06-05 2017-04-26 武田薬品工業株式会社 固形製剤
WO2014065427A1 (ja) * 2012-10-26 2014-05-01 株式会社 三和化学研究所 アナグリプチン含有固形製剤
EP2769712A1 (en) 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
EP2915528A1 (en) 2014-03-06 2015-09-09 Sanovel Ilac Sanayi ve Ticaret A.S. Vildagliptin formulation process under inert gas atmosphere
WO2018050892A1 (en) 2016-09-16 2018-03-22 Galenicum Health S.L. Vildagliptin pharmaceutical compositions
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
GR1009406B (el) * 2017-10-03 2018-11-26 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
KR102622198B1 (ko) 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
GR1009644B (el) 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
BE1026818B1 (fr) * 2018-11-30 2020-06-30 Hedelab Sa Procede de fabrication d'une serie de n preparations pour complements alimentaires
KR102693304B1 (ko) 2019-04-16 2024-08-08 한미약품 주식회사 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
JP7461735B2 (ja) * 2019-12-02 2024-04-04 日本ジェネリック株式会社 ビルダグリプチン含有錠剤
CN113018270A (zh) * 2019-12-24 2021-06-25 四川科瑞德制药股份有限公司 一种高稳定的盐酸米那普仑制剂及其制备方法
WO2024033460A1 (en) * 2022-08-12 2024-02-15 F. Hoffmann-La Roche Ag Use of co-processed excipients in continuous manufacturing of solid dosage forms

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131402A1 (de) * 1981-08-07 1983-02-24 Kilian & Co GmbH, 5000 Köln Verfahren und tablettenpresse zum aufeinanderfolgenden herstellen einer vielzahl von tabletten mit gleichem gewicht
US4894236A (en) * 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
DE3833448A1 (de) * 1988-10-01 1990-04-12 Hoechst Ag Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
JP3784084B2 (ja) * 1993-10-21 2006-06-07 武田薬品工業株式会社 医薬用錠剤
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP1043328B1 (en) 1997-11-18 2008-03-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel physiologically active substance sulphostin, process for producing the same, and use thereof
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
EP1062222A1 (en) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
JP4880120B2 (ja) 1998-07-10 2012-02-22 日本発條株式会社 導電性接触子
US6088938A (en) 1998-07-17 2000-07-18 Logan; John Duncan Implement adapter for an excavation tool assembly
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1228061A4 (en) 1999-11-12 2004-12-15 Guilford Pharm Inc DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS
NZ519086A (en) * 1999-11-30 2003-11-28 Dainippon Pharmaceutical Co Solid preparation
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2001055105A1 (en) 2000-01-24 2001-08-02 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2003528135A (ja) 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
US6482844B1 (en) 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
MXPA02012272A (es) 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
CA2424600C (en) 2000-10-06 2008-12-02 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US20040180925A1 (en) 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
WO2002066627A1 (en) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation of human dipeptidyl peptidase 8
SI1953162T1 (sl) 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
WO2002067918A1 (en) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative
EP1385508B1 (en) 2001-03-27 2008-05-21 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2822826B1 (fr) * 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
JP2004538266A (ja) 2001-04-27 2004-12-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド ピラゾール由来のキナーゼインヒビター
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
SE523510C2 (sv) 2001-05-18 2004-04-27 Jan G Faeger Förfarande för att fastställa en varelses position och/eller orientering i förhållande till en omgivning
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
RU2299066C2 (ru) 2001-06-27 2007-05-20 Пробиодруг Аг Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
WO2003003250A1 (en) 2001-06-28 2003-01-09 Hywire Ltd. Range content-addressable memory
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
TWI246510B (en) 2001-09-14 2006-01-01 Mitsubishi Pharma Corp Thiazolidine derivatives and pharmaceutical uses thereof
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
MXPA04006780A (es) * 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
DE60323823D1 (de) 2002-01-11 2008-11-13 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
CN1324015C (zh) 2002-02-13 2007-07-04 霍夫曼-拉罗奇有限公司 吡啶－和嘧啶－衍生物
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003214534B2 (en) 2002-04-08 2006-08-31 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2003327532A (ja) * 2002-05-10 2003-11-19 Takeda Chem Ind Ltd ペプチダーゼ阻害剤
CN100402026C (zh) 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
HRP20050343A2 (en) 2002-10-18 2007-03-31 Merck & Co. Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
DE10256264A1 (de) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
WO2004076433A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
AR044019A1 (es) 2003-04-16 2005-08-24 Novartis Ag Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas
JP5122144B2 (ja) 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral

Similar Documents

Publication Publication Date Title
CA2552569A1 (en) Direct compression formulation and process
KR100696350B1 (ko) 급속 방출 정제
JP5622575B2 (ja) 固形バルサルタン組成物
SK284049B6 (sk) Orálny prostriedok a spôsob jeho prípravy
TW202139977A (zh) 包括阿托伐他汀以及怡妥錠的雙層片劑及其製造方法
CN101219120B (zh) 替米沙坦分散片及其制备方法
US20120107397A1 (en) Pharmaceutical compositions of valsartan
CN105407925A (zh) 用于泡腾剂型的制造工艺
EP3793529A1 (en) Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
WO2010057449A2 (en) A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances
WO2010120963A1 (en) Tablet formulation for p38 inhibitor and method
WO2000071117A1 (en) Immediate release medicinal compositions for oral use
US20080008751A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
JP5113476B2 (ja) 保存安定性に優れた塩酸テモカプリルの錠剤
RU2007147949A (ru) Композиция, содержащая ингибиторы dpp-iv глитазоны, полученная прямым прессованием, и способ ее получения
CA2454449A1 (en) Synergistic filler composition of pvp-va and silicified mycrocrystalline cellulose for tablet dosage form
TH74669A (th) สูตรและกรรมวิธีการอัดแบบโดยตรง
CN102028670A (zh) 一种包含替米沙坦和钙离子通道拮抗剂的复方胶囊剂
JP7437039B2 (ja) 錠剤
CN101590042B (zh) 稳定的口服药物组合物
JP2007182400A (ja) 経時安定性に優れたメロキシカム含有錠剤組成物
US20030229101A1 (en) Tablets comprising ciprofloxacin hydrochloride
TH85413A (th) สูตรตำรับยาชนิดตอกโดยตรง และกระบวนการ
CA2659814A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
EP1889629A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof